Skip to main content
. 2017 May 16;16:65. doi: 10.1186/s12933-017-0547-1

Fig. 1.

Fig. 1

The action sites of SGLT2 and RASS inhibitors and the potential synergistic mechanism of their combined therapy in T2DM. RASS renin–angiotensin-aldosterone system, T2DM type 2 diabetes mellitus, SGLT2 Sodium–glucose co-transporter 2